Medical and Diagnostic Laboratories (U.S.) — An Investor's Primer

NAICS 2022 code 62151. A general-audience rollup for both public-market and private investors. (NAICS = North American Industry Classification System, the U.S. government's standard for grouping businesses.) This is the level that sits one rung above the two businesses most people picture when they think "outpatient diagnostics": the labs that analyze your blood and tissue, and the centers that scan the inside of your body.

1. Overview

When a doctor needs to find out what is wrong with you, the answer usually comes from one of two places: a laboratory that analyzes a physical specimen — blood, urine, a tissue biopsy, a cheek swab — or an imaging center that produces a picture of your insides — an MRI, CT scan, ultrasound, or mammogram — for a radiologist to interpret. Neither treats the patient. Both turn a sample or a signal into a result a physician can act on. Together they are the diagnostic layer of American medicine, and NAICS 62151 is the government's bucket for the freestanding, outpatient version of both.[1]

The level bundles two industries that look alike from a distance and behave differently up close:

• 621511 — Medical Laboratories: the independent labs that run blood chemistry, pathology, and increasingly genomic and molecular tests.[3]
• 621512 — Diagnostic Imaging Centers: the standalone facilities that produce MRI, CT, X-ray, ultrasound, and PET images.[4]

Both share the same three big virtues for an investor: defensive, recurring demand (people get sick regardless of the economy), a powerful demographic tailwind (an aging, chronically ill population needs more tests and scans every year), and high operating leverage (once the facility and equipment are built, each additional specimen or scan is highly profitable). Both also share the same defining vulnerability: they do not set most of their own prices — government fee schedules and insurers do.

The reason to read the two together — and the real value of a rollup — is that they are not the same investment. One is a concentrated, public-market-friendly business dominated by two national giants; the other is a fragmented, overwhelmingly private business built on private-equity roll-ups and hospital partnerships. The rest of this primer is mostly about that contrast, and what the combined level looks like once you net the two out.

One caveat up front, and it applies to the whole level: these are the freestanding diagnostics businesses only. The majority of U.S. lab testing and imaging actually happens inside hospitals and inside doctors' offices, which NAICS files under different codes. So NAICS 62151 is a large, real, but partial slice of total U.S. diagnostics (Section 3).

2. What's inside — the two child industries and how they differ

Both children take in an order, do a technical procedure on the patient or their specimen, have a physician (a pathologist for labs, a radiologist for imaging) interpret it, and bill a payer. The economics rhyme — high fixed costs, volume-driven, price-taking — but the shape of the two industries could hardly be more different. This is the heart of the rollup:

How to read the table. Labs are roughly twice the size of imaging on every physical measure — revenue, locations, employees — and they are far more concentrated: in labs, the top four firms (led by Quest and Labcorp) take 36% of revenue, versus a strikingly fragmented 12.9% in imaging. That single contrast drives almost everything downstream. Because labs are big, concentrated, and public-company-led, an ordinary investor can actually buy the lab industry on a stock exchange. Because imaging is fragmented and private-equity-owned, an ordinary investor mostly cannot — the realistic routes are private funds, hospital-JV structures, or owning centers directly. Same NAICS parent; two different games.

3. How big it is — the combined level

Our ground-truth federal statistics for NAICS 62151 as a whole. Years differ by source (revenue and concentration from the 2022 Economic Census; counts and payroll from 2023 County Business Patterns) and should not be blended into a single-period estimate.

The children add up — a useful cross-check. Labs ($56.1B) plus imaging ($25.0B) equal the level's $81.1B exactly; establishments (16,635 + 6,968 = 23,603) and employment (232,333 + 99,727 = 332,060) also sum precisely.[2][3][4] The one figure that does not simply add is the firm count: the two children list 4,527 + 4,717 = 9,244 firms, but the level reports 9,154 — about 90 fewer, because a company that operates in both labs and imaging is counted once at this level. It is a small hint that a handful of operators (the diversified majors above all) straddle both businesses.

Concentration at the level is deceptively moderate. For NAICS 62151 the top 4 firms hold 24.9% of revenue, the top 8 29.9%, the top 20 38.3%, and the top 50 49.6% — so half of all revenue sits outside the 50 biggest companies.[2] The level's Herfindahl-Hirschman Index (HHI, a standard concentration gauge) is suppressed in the federal data, so we neither state nor estimate it. But that middling blended figure is an average of two opposite structures: a concentrated lab tier (top-4 = 36%) welded to a fragmented imaging tier (top-4 = 12.9%). The level looks moderately consolidated; neither child actually is.

Undercount caveat — important at every level here. The $81.1B is real but partial, for two reasons. By design: NAICS 62151 excludes labs and imaging performed inside hospitals (NAICS 622) and inside physician offices (NAICS 6211), which is where the majority of U.S. testing and scanning happens — so the true "diagnostics" economy across all settings runs into the hundreds of billions, with total clinical-lab testing alone estimated around $80–90B+ and hospital labs accounting for more than half of that.[11] By survey method: County Business Patterns excludes the self-employed, non-employer businesses, and most government workers, and the Economic Census targets paid-employee establishments and generally excludes government-owned ones.[10] So these figures accurately size the employer-based, freestanding diagnostics economy — not total U.S. diagnostics, and they can under-represent very small owner-operated practices and public/VA/academic facilities. Our data contain no volume, utilization, payer-mix, or margin figures for the level; those come from company and industry sources below.

4. The investable universe — where value concentrates across the children

The single most important fact for a stock investor: the public-market opportunity is almost entirely in the lab child, not the imaging child. Labs are ~69% of the level's revenue but a far larger share of its investable public value, because the imaging side has been absorbed by private equity. Tickers and figures below are reserved to this section and Section 10; figures are most recent full-year 2025 unless noted.

Labs (621511) — genuine public depth. Two national pure-play giants anchor the segment: Labcorp (NYSE: LH, ~$13.95B total revenue, of which a ~$10.9B Diagnostics segment is the comparable lab business and ~22% is a separate biopharma/contract-research arm) and Quest Diagnostics (NYSE: DGX, ~$11.0B, essentially a pure diagnostic-testing company).[5][6] Behind them sits a real cohort of faster-growing, higher-risk specialty / molecular / genomic testers — Exact Sciences (NASDAQ: EXAS), Natera (NASDAQ: NTRA), Guardant Health (NASDAQ: GH), NeoGenomics (NASDAQ: NEO), Veracyte (NASDAQ: VCYT), Fulgent Genetics (NASDAQ: FLGT), plus CareDx and Myriad Genetics — several still unprofitable but growing 20–40%.[8] Some of the most respected labs (Mayo Clinic Laboratories, ARUP, Cleveland Clinic) are non-profit academic reference operations and not investable at all.

Imaging (621512) — thin public, deep private. The entire public menu is essentially RadNet (Nasdaq: RDNT, ~$2.04B revenue, ~418 centers, plus a fast-growing DeepHealth AI-software arm), the newly public Lumexa Imaging (Nasdaq: LMRI, formerly US Radiology Specialists), and micro-cap Fonar (Nasdaq: FONR).[4][7] Hospital operators like HCA and Tenet run imaging but do not disclose its economics separately. Where the imaging industry actually lives is private: PE-backed chains such as SimonMed (American Securities), RAYUS Radiology (Wellspring), Solis Mammography (TowerBrook), Akumin (Stonepeak), and Envision Radiology, plus a wide field of hospital joint ventures.[4]

The synthesis. If you want the level in one trade, you are really buying the lab majors — Quest and Labcorp are the closest thing to a "buy NAICS 62151" ticker, and even they skew toward the lab side. To touch imaging as a public investor you reach for RadNet or Lumexa; to own it in size you go private. Value in this level concentrates at the scaled top of labs (durable cash flows) and in the fragmented middle of imaging (roll-up opportunity) — two very different value pools under one code.

5. How the money works

Both children are high-fixed-cost, high-volume, price-taking businesses that make money on the spread between what a payer reimburses per test or scan and the marginal cost of producing it. In both, the master lever is utilization — keeping expensive equipment and specialized staff busy — because once the fixed base is built, incremental volume is highly profitable. A shared shorthand:

Revenue ≈ volume × realized reimbursement per unit.

For labs, "volume" is measured in requisitions (a doctor's order, which may bundle several tests) and the reimbursement mix shifts up as routine chemistry gives way to high-priced molecular and genomic assays.[3][5] For imaging, "volume" is exams, and reimbursement per exam is a blend of modality mix (an MRI or PET pays far more than an X-ray) and payer mix (commercial pays most, Medicare less, Medicaid least).[4]

Where the economics diverge:

• Capital intensity. Imaging is the more capital-hungry of the two per site: a single MRI or PET/CT scanner can cost low millions, so the model is frequently debt-financed — which magnifies returns when machines are busy and becomes dangerous when volumes or reimbursement dip (Akumin's 2023 Chapter 11, which wiped out roughly $470M of debt, is the object lesson).[4] Labs are capital-intensive too, but their automation lines and courier logistics are centralized and shareable across enormous volume, which is why the lab majors are such strong, steady cash generators (Labcorp ~$1.21B free cash flow, Quest ~$1.9B operating cash flow in 2025).[5][6]
• Who pays and how prices are set. Labs are paid largely off Medicare's CLFS (Clinical Laboratory Fee Schedule), which under PAMA (Protecting Access to Medicare Act of 2014) is pegged to the median price private insurers actually pay.[3] Imaging is paid off Medicare's MPFS (Physician Fee Schedule), whose conversion factor has trimmed roughly 10% over a decade and anchors many commercial contracts.[4] Either way, the revenue line is exposed to administered prices the operator does not control.
• The newer margin story. Both children increasingly monetize software and AI on top of the core service — RadNet's DeepHealth in imaging, and automation/AI-assisted interpretation in labs — which lifts throughput and adds a higher-margin revenue stream.[4]

Across the level, the specialty testers are the exception to the "steady cash" rule: they deliberately burn cash to build volume and win insurance coverage for novel tests, betting on scale later. Our federal data include no level-wide margin, utilization, or reimbursement figures, so none are asserted here.

6. What drives demand

The two children are pulled by largely the same forces, which is why they sit under one parent:

• Aging demographics. Adults 65+ reached 61.2 million (18.0% of the population) in 2024 and are the heaviest users of both testing and imaging; the cohort keeps growing into 2030.[18] This is the level's most durable tailwind.
• Chronic disease. Diabetes, cardiovascular disease, and cancer all generate recurring tests and scans for diagnosis and monitoring — repeat volume, not one-offs.[3][4]
• Early detection and precision medicine. Genomic tumor profiling, hereditary-risk and prenatal testing, and broadening imaging-screening guidelines (mammography, low-dose lung CT) pull people into diagnostics on a schedule — the fastest-growing, highest-priced categories in both children.[3][4]
• Site-of-service migration and outsourcing. The structural tailwind unique in emphasis to imaging: because an identical scan costs far less in a freestanding center than in a hospital, insurers and employers actively steer patients out of hospitals.[4] Labs have a parallel dynamic — hospital systems increasingly sell their outreach labs to Quest and Labcorp rather than run them.[3]
• AI and automation. Faster interpretation lets a fixed base of scanners, instruments, radiologists, and pathologists handle more volume — efficiency first, with a software-revenue kicker.[4]

The common caution: diagnostics is defensive but not perfectly recession-proof. Volume tracks physician visits, elective procedures, and employment-linked insurance coverage, softens when patients defer care, and was distorted by the COVID-19 surge and its normalization.

7. Regulation

Both children are heavily regulated, and in both, regulation is simultaneously a moat (barriers to entry) and a risk (prices and rules set by others). The categories overlap; the specific regimes differ by child.

Shared across the level:

• Reimbursement set by CMS (Centers for Medicare & Medicaid Services): the CLFS for labs, the MPFS for imaging — both administered price lists that also anchor commercial contracts.[3][4][12][13]
• Fraud-and-abuse and self-referral law: the Anti-Kickback Statute, the Stark Law (which explicitly names clinical-lab services and restricts referrals to facilities a physician has a stake in), and the False Claims Act govern how both bill and take referrals.[3][4]
• Privacy and cybersecurity: HIPAA (Health Insurance Portability and Accountability Act) safeguards for the large volumes of protected health information both hold.[3][4]
• State licensure and market-entry rules layer on top of the federal floor.

Specific to labs (621511):

• CLIA (Clinical Laboratory Improvement Amendments of 1988) — the license to operate; any lab testing human specimens must hold a CLIA certificate, graded by test complexity.[3]
• The Laboratory-Developed Test (LDT) swing — the FDA's 2024 rule to regulate in-house tests as devices was vacated by a federal court in March 2025 and formally reverted by the FDA in September 2025, lifting a major overhang for the specialty testers.[14]

Specific to imaging (621512):

• IDTF (Independent Diagnostic Testing Facility) Medicare enrollment; MIPPA-required accreditation (e.g., American College of Radiology) to be paid for advanced imaging; MQSA (Mammography Quality Standards Act) FDA certification for mammography; NRC/state oversight of radioactive materials; state Certificate-of-Need laws that gate buying a scanner or opening a center; and appropriate-use / prior-authorization controls on utilization.[4]

8. Consolidation

Consolidation is the defining trend across the whole level — but it runs on two different clocks.

• Labs are consolidating from an already-concentrated top. The two majors (Quest, Labcorp) keep buying regional labs, molecular/oncology capabilities, and — increasingly — hospital systems' outreach labs, pulling volume that once sat with many small local operators onto two national platforms. Private equity is also rolling up regional and physician-led pathology groups.[3] The direction is more concentration on top of a segment where the top four already hold 36%.
• Imaging is consolidating from a fragmented base — a long runway. With ~6,900 facilities and the top eight firms under 19% of revenue, imaging is where the roll-up story is youngest and largest. Two acquirer classes are running it down: private equity (the most aggressive consolidator; PE-employed radiologists jumped from ~1% to ~12% of the profession in a decade) and hospital/health-system joint ventures, where systems partner with an operator rather than build outpatient sites themselves.[4] Documented result: PE- and hospital-affiliated radiologists negotiate materially higher commercial prices than independents — scale converting into payer-negotiating power.[4]

The unifying logic is the same in both children: scale wins the commoditized, price-pressured core (routine tests, routine scans) through lower unit cost and stronger payer contracts, so the sub-scale independent gets squeezed and the well-capitalized consolidator buys them. The difference is simply how far along each is — labs are late-innings at the top, imaging is early-innings across a fragmented field.

9. Risks

The two children largely share a risk profile, with a couple of child-specific accents:

• Reimbursement / pricing power — the biggest risk in both. Neither labs nor imaging set most of their own prices; PAMA-driven CLFS cuts and MPFS conversion-factor erosion push routine-work prices structurally down, and commercial payers push the same way.[3][4] Recent PAMA delays (no cut in 2026, future cuts capped) have softened but not removed the pressure.[12]
• Coverage lag for new tests / utilization controls. A clinically valuable new genomic test can go unpaid for years until payers grant coverage (the specialty-lab risk); prior authorization and benefit-management programs deny or delay scans (the imaging risk).[3][4]
• Labor. Shortages of pathologists, radiologists, medical technologists, and technicians raise costs and cap throughput in both children.
• Leverage — sharper in imaging. The debt-financed, capital-heavy roll-up model is fragile when volumes wobble; Akumin's bankruptcy is the cautionary case.[4]
• Commoditization of the routine core. High-volume, low-price tests and scans are a race to lowest cost that punishes subscale operators.
• Compliance, quality, and cybersecurity. Complex multi-payer billing invites False Claims Act / anti-kickback exposure; CLIA/MQSA quality lapses and missed or wrong results carry clinical and legal consequences; both hold large troves of protected health information and are standing breach targets.[3][4]
• Technology / channel disruption. Point-of-care, at-home, and direct-to-consumer testing could pull volume from central labs; hospitals may retain testing and imaging internally rather than outsource.
• Disclosure risk for private investors. Most of the imaging industry and much of the lab tail are private and disclose far less than public companies, and the federal data omit hospital, physician-office, and very-small-operator activity — so private diligence carries an added information gap.

10. How to invest, and the outlook

Public-market route — mostly a bet on labs. The deepest public exposure to NAICS 62151 is the lab majors: Quest (DGX) and Labcorp (LH) — GDP-plus volume growth, real margins, dividends and buybacks, and the role of consolidator (remembering Labcorp's ~22% biopharma/CRO arm is not 621511 revenue).[5][6] For growth, the molecular/genomic testers (EXAS, NTRA, GH, NEO, VCYT, FLGT, plus CareDx and Myriad) offer 20–40% growth at higher valuation risk, several still unprofitable.[8] Imaging's public menu is thin: RadNet (RDNT) (with a software/AI kicker) and newly public Lumexa (LMRI) are the direct plays; HCA and THC bury imaging inside hospital results.[4][7] Analyze public names on organic volume, revenue per requisition/scan, reimbursement trends, specialty/advanced-modality mix, margins, free cash flow, capital spending, leverage, and business purity.

Private-market route — mostly a bet on imaging (and the lab tail). This is where most of the level actually is for a direct investor. On the imaging side: PE healthcare-services funds, direct ownership or roll-up of independent centers (the SBA's $19.0M receipts threshold shows how small a typical target is), hospital-JV structures, private credit, and the real estate under the centers.[4][9] On the lab side: PE-backed regional lab platforms and physician-led pathology groups, laboratory-management contracts, and venture funding of diagnostic startups chasing coverage for a new test.[3] Diligence should center on CLIA/MQSA and state licensure, payer contracts and denial trends, equipment utilization and scanner/instrument age, physician (pathologist/radiologist) retention, customer concentration, normalized earnings, leverage and JV waterfalls, and integration risk. The marquee academic reference labs (Mayo, ARUP, Cleveland Clinic) are off-limits — non-profit or health-system-owned.

Editorial judgment. The combined level is a defensive, demographically favored, consolidating industry whose ceiling is set less by demand than by what payers will pay. Base case: aging and chronic disease keep volumes rising, precision-medicine testing and advanced-imaging mix keep pulling revenue per unit up, and consolidation keeps concentrating both children — labs from an already-concentrated top, imaging from a fragmented base. The durable winners share one trait across both children: either genuine scale (lowest cost per test or scan) or a differentiated, well-reimbursed menu (a proprietary molecular test, a high-value advanced-imaging mix). The weakest investments lean on temporary volume surges, uncertain reimbursement, weak billing controls, or excess leverage. For most public investors, "owning NAICS 62151" in practice means owning the lab giants; owning the imaging half means going private — and that split, more than any single number, is the point of reading the two together.

---

Sources

1. U.S. Census Bureau / NAICS, "2022 NAICS: 62151 Medical and Diagnostic Laboratories" and child codes 621511 / 621512 (definitions, inclusions, and excluded hospital/physician-office codes 622 and 6211). https://www.census.gov/naics/?input=62151&year=2022
2. Ingested ground-truth federal statistics for NAICS 62151 — U.S. Census Bureau 2022 Economic Census, Concentration of Largest Firms (receipts $81.1B; 9,154 firms; CR4 24.9%, CR8 29.9%, CR20 38.3%, CR50 49.6%; HHI suppressed) and County Business Patterns 2023 (23,603 establishments; 332,060 employees; $24.7B annual payroll; $6.35B first-quarter payroll).
3. Child primer, NAICS 621511 — Medical Laboratories (U.S.) (receipts $56.1B; 4,527 firms; 16,635 establishments; 232,333 employees; concentration CR4 36% / CR8 41.8% / CR20 51.7% / CR50 62.7%; ownership mix; CLIA / CLFS / PAMA / LDT regulation; Quest and Labcorp as scale operators; specialty-tester cohort). Draws on 2022 Economic Census, 2023 County Business Patterns, and company disclosures cited therein.
4. Child primer, NAICS 621512 — Diagnostic Imaging Centers (U.S.) (receipts $25.0B; 4,717 firms; 6,968 establishments; 99,727 employees; concentration CR4 12.9% / CR8 18.9% / CR20 30.0% / CR50 43.9%; HHI 76.1; PE and hospital-JV ownership; MPFS / IDTF / MIPPA / MQSA regulation; RadNet, Lumexa, Fonar; Akumin leverage case; site-of-service migration). Draws on 2022 Economic Census, 2023 County Business Patterns, and company/industry sources cited therein.
5. Quest Diagnostics Inc., "Fourth Quarter and Full Year 2025 Financial Results" and 2025 Form 10-K (FY2025 revenue ~$11.0B; ~244M requisitions; requisition volume and revenue per requisition as core metrics; ~$1.9B operating cash flow), Feb 2026. https://www.sec.gov/Archives/edgar/data/1022079/000102207926000015/dgx-20251231.htm
6. Labcorp Holdings Inc., "2025 Fourth Quarter and Full Year Results" and 2025 Form 10-K (FY2025 revenue ~$13.95B; Diagnostics ~$10.9B / ~78%; biopharma ~22%; ~$1.21B free cash flow), Feb 2026. https://www.sec.gov/Archives/edgar/data/920148/000092014826000111/lh-20251231.htm
7. RadNet, Inc., "Fourth Quarter 2025 Results and 2026 Guidance" and 2025 Form 10-K (FY2025 revenue ~$2.04B; ~418 centers; ~15% adjusted-EBITDA margin; DeepHealth digital-health arm), 2026. https://www.sec.gov/Archives/edgar/data/790526/000162828026013337/rdnt-20251231.htm
8. Specialty / molecular / genomic testers, FY2025 results — Exact Sciences (EXAS), Natera (NTRA), Guardant Health (GH), NeoGenomics (NEO), Veracyte (VCYT), Fulgent Genetics (FLGT); as compiled in the 621511 child primer, Feb 2026.
9. U.S. Small Business Administration, Table of Small Business Size Standards (NAICS 621511 = $41.5M receipts; 621512 = $19.0M receipts), 2023. https://www.sba.gov/document/support-table-size-standards
10. U.S. Census Bureau, "County Business Patterns Methodology" and "2022 Economic Census Methodology" (CBP excludes self-employed, non-employer, and most government workers; Economic Census targets paid-employee establishments and generally excludes government-owned ones). https://www.census.gov/programs-surveys/cbp/technical-documentation/methodology.html
11. Grand View Research / Mordor Intelligence / Fortune Business Insights, clinical-laboratory-services and diagnostic-imaging-services market sizing (total U.S. clinical-lab testing ~$80–90B+; hospital labs >50% of testing revenue; total imaging services measured in the hundreds of billions), 2025. https://www.grandviewresearch.com/industry-analysis/clinical-laboratory-services-market
12. Centers for Medicare & Medicaid Services, "Clinical Laboratory Fee Schedule / PAMA Reporting Resources" (CLFS administered pricing; PAMA private-payer-median peg; CY2025 0% reduction; CAA 2026 delay; 15%/yr caps 2027–2029), 2025–2026. https://www.cms.gov/medicare/payment/fee-schedules/clinical-laboratory-fee-schedule/clfs-pama-reporting-resources
13. Centers for Medicare & Medicaid Services / Radiology Business, "Medicare Physician Fee Schedule 2025" (conversion factor −2.83%; ~10% erosion over a decade). https://info.hapusa.com/blog-0/medicare-finalizes-2025-fee-schedule-cut
14. Sidley Austin LLP / American Hospital Association, "FDA's Laboratory-Developed Tests (LDT) Rule Struck Down / FDA vacates LDT rule" (federal court vacated the rule Mar 31, 2025; FDA reverted Sept 19, 2025). https://www.aha.org/news/headline/2025-09-18-fda-vacates-final-rule-regulating-lab-developed-tests-medical-devices
15. American College of Radiology / U.S. FDA / CMS, imaging-specific regimes — ACR accreditation (MIPPA), MQSA mammography certification, and IDTF Medicare enrollment. https://www.acr.org/Accreditation; https://www.fda.gov/radiation-emitting-products/mammography-quality-standards-act-mqsa-and-mqsa-program
16. Centers for Medicare & Medicaid Services, "Clinical Laboratory Improvement Amendments (CLIA)" (certification required for any lab testing human specimens; graded by complexity). https://www.cms.gov/medicare/quality/clinical-laboratory-improvement-amendments
17. Radiology Business / Becker's Hospital Review / Journal of the American College of Radiology, consolidation evidence (PE-employed radiologists ~1%→~12% in a decade; higher negotiated prices for PE- and hospital-affiliated groups; health-system outreach-lab sales to Quest/Labcorp), 2024–2026. https://www.jacr.org/article/S1546-1440(25)00403-X/fulltext
18. U.S. Census Bureau, "Older Adults Outnumber Children in 11 States…" (61.2M / 18.0% aged 65+ in 2024) and American Society for Clinical Laboratory Science on the geriatric testing tailwind (nearly 1 in 5 aged 65+ by 2030), 2025. https://www.census.gov/newsroom/press-releases/2025/older-adults-outnumber-children.html